-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
HC Wainwright Comments on Biomea Fusion, Inc.'s FY2027 Earnings (NASDAQ:BMEA)
HC Wainwright Comments on Biomea Fusion, Inc.'s FY2027 Earnings (NASDAQ:BMEA)
Biomea Fusion, Inc. (NASDAQ:BMEA – Get Rating) – Investment analysts at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Biomea Fusion in a note issued to investors on Friday, January 13th. HC Wainwright analyst J. Pantginis expects that the company will earn ($2.50) per share for the year. HC Wainwright has a "Buy" rating and a $37.00 price target on the stock. The consensus estimate for Biomea Fusion's current full-year earnings is ($2.74) per share.
Get Biomea Fusion alerts:Biomea Fusion (NASDAQ:BMEA – Get Rating) last issued its quarterly earnings results on Monday, November 7th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.65) by ($0.13).
Separately, EF Hutton Acquisition Co. I cut their price objective on Biomea Fusion from $27.00 to $22.00 and set a "buy" rating for the company in a research report on Tuesday, November 8th.Biomea Fusion Stock Performance
Shares of NASDAQ:BMEA opened at $7.44 on Monday. Biomea Fusion has a one year low of $2.84 and a one year high of $14.20. The stock has a fifty day moving average of $7.59 and a 200-day moving average of $9.85. The company has a market capitalization of $218.71 million, a PE ratio of -3.05 and a beta of -1.85.
Insider Activity
In other Biomea Fusion news, Director Michael J.M. Hitchcock bought 5,000 shares of Biomea Fusion stock in a transaction dated Monday, November 14th. The stock was bought at an average price of $7.93 per share, for a total transaction of $39,650.00. Following the completion of the acquisition, the director now directly owns 5,000 shares of the company's stock, valued at $39,650. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 45.70% of the company's stock.
Institutional Trading of Biomea Fusion
A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. lifted its holdings in shares of Biomea Fusion by 2.0% in the first quarter. BlackRock Inc. now owns 1,705,442 shares of the company's stock valued at $7,606,000 after purchasing an additional 32,634 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Biomea Fusion by 18.5% during the third quarter. Vanguard Group Inc. now owns 803,118 shares of the company's stock worth $7,854,000 after acquiring an additional 125,311 shares in the last quarter. Laurion Capital Management LP raised its holdings in shares of Biomea Fusion by 2.2% during the third quarter. Laurion Capital Management LP now owns 429,400 shares of the company's stock worth $4,200,000 after acquiring an additional 9,251 shares in the last quarter. Citadel Advisors LLC raised its holdings in shares of Biomea Fusion by 540.5% during the second quarter. Citadel Advisors LLC now owns 335,191 shares of the company's stock worth $4,016,000 after acquiring an additional 282,855 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Biomea Fusion by 1,475.9% during the second quarter. JPMorgan Chase & Co. now owns 273,925 shares of the company's stock worth $3,281,000 after acquiring an additional 256,543 shares in the last quarter. Hedge funds and other institutional investors own 50.28% of the company's stock.
About Biomea Fusion
(Get Rating)
Biomea Fusion, Inc, a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers.
See Also
- Get a free copy of the StockNews.com research report on Biomea Fusion (BMEA)
- General Electric Stock, The Sum of All Parts Strategy is Paying Off
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.com's FREE daily email newsletter.
生物美亞融合公司(納斯達克代碼:BMEA-GET Rating)-在1月13日星期五發布的一份給投資者的報告中,HC Wainwright的投資分析師發佈了他們對生物美亞融合公司股票2027財年每股收益的估計。HC Wainwright分析師J·潘特吉尼斯預計,該公司今年的每股收益將達到2.50美元。HC Wainwright對該股的評級為買入,目標價為37.00美元。對Biomea Fusion目前全年收益的普遍估計是每股2.74美元。
到達生物群融合警報:生物美發(納斯達克代碼:BMEA-GET Rating)最近一次發佈季度收益報告是在11月7日(星期一)。該公司公佈本季度每股收益(EPS)為0.78美元,低於分析師一致預期的0.65美元和0.13美元。
另外,EF Hutton Acquisition Co.I將Biomea Fusion的目標價從27.00美元下調至22.00美元,並在11月8日星期二的一份研究報告中為該公司設定了買入評級。Biomea Fusion股票表現
納斯達克:非洲、中東和非洲股票週一開盤報7.44美元。Biomea Fusion的一年低點為2.84美元,一年高位為14.20美元。該股的50日移動均線為7.59美元,200日移動均線為9.85美元。該公司市值為2.1871億美元,本益比為-3.05,貝塔係數為-1.85。
內幕活動
在另一則關於Biomea Fusion的消息中,董事邁克爾·J·M·希區柯克在一筆日期為11月14日(星期一)的交易中購買了5,000股Biomea Fusion股票。這只股票是以每股7.93美元的平均價格購買的,總交易金額為39,650.00美元。收購完成後,董事現在直接擁有5,000股該公司股票,價值39,650美元。這筆交易是在提交給美國證券交易委員會的一份檔案中披露的,該檔案可通過美國證券交易委員會網站。公司內部人士持有該公司45.70%的股份。
Biomea融合的機構性交易
多家對沖基金最近調整了對該業務的持股。貝萊德股份有限公司在第一季度增持了Biomea Fusion的股份2.0%。貝萊德股份有限公司在上個季度增持了32,634股後,現在持有1,705,442股該公司股票,價值7,606,000美元。先鋒集團(Vanguard Group Inc.)在第三季度將其持有的Biomea Fusion股票增加了18.5%。先鋒集團(Vanguard Group Inc.)在上個季度增持了125,311股後,目前持有803,118股公司股票,價值7,854,000美元。Laurion Capital Management LP在第三季度將其在Biomea Fusion的股票持有量增加了2.2%。Laurion Capital Management LP在上個季度額外收購了9251股後,現在擁有429,400股該公司股票,價值4,200,000美元。Citadel Advisors LLC在第二季度將其持有的Biomea Fusion股票增加了540.5%。Citadel Advisors LLC在上個季度增持了282,855股後,現在擁有335,191股該公司股票,價值4,016,000美元。最後,摩根大通在第二季度將其持有的Biomea Fusion股票增加了1,475.9%。摩根大通公司目前持有273,925股該公司股票,價值3,281,000美元,上個季度又購入了256,543股。對沖基金和其他機構投資者持有該公司50.28%的股票。
關於Biomea Fusion
(獲取評級)
Biomea Fusion,Inc.是一家生物製藥公司,專注於發現和開發共價小分子藥物,用於治療基因定義的癌症和代謝性疾病患者。它的主要候選產品是BMF-219,一種口服生物可用、有效和選擇性的薄荷素共價抑制劑,它是多種癌症致癌信號中的轉錄調節因數。
另請參閱
- 免費獲取StockNews.com關於Biomea Fusion(BMEA)的研究報告
- 通用電氣股票,所有部件的總和戰略正在奏效
- MarketBeat:回顧中的一週01/09-01/13
- 摩根大通破產,銀行為衰退做好準備
- 為什麼Bed Bath&Beyond的股價上漲了261%?
- Roku股價走勢,原因如下
接受Biomea Fusion Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Biomea Fusion和相關公司的最新新聞和分析師評級的每日簡明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧